Annexon, Inc. (NASDAQ:ANNX) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in Annexon, Inc. (NASDAQ:ANNX) by 1.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 743,795 shares of the company’s stock after purchasing an additional 11,579 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.70% of Annexon worth $3,816,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. State Street Corp lifted its position in shares of Annexon by 116.6% during the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after acquiring an additional 2,068,294 shares during the period. Sio Capital Management LLC acquired a new stake in shares of Annexon in the third quarter worth $8,484,000. Mutual of America Capital Management LLC raised its holdings in shares of Annexon by 56.2% during the 4th quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company’s stock valued at $5,282,000 after buying an additional 370,426 shares during the period. Geode Capital Management LLC grew its holdings in Annexon by 18.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock valued at $12,693,000 after purchasing an additional 331,269 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in Annexon in the third quarter valued at about $1,946,000.

Annexon Price Performance

Shares of ANNX opened at $2.29 on Thursday. The stock has a market capitalization of $251.24 million, a PE ratio of -2.18 and a beta of 1.14. The business’s fifty day moving average price is $3.12 and its 200 day moving average price is $5.03. Annexon, Inc. has a 12-month low of $2.28 and a 12-month high of $8.40.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). As a group, research analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Annexon in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Annexon has an average rating of “Buy” and an average target price of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.